Generative vs. discriminative models in ML:(a popular ML interview question) https://t.co/fVVwZBkCVR ...

Core Viewpoint - One Stop Systems Inc. (NASDAQ:OSS) is identified as a promising AI stock under $10, with recent price target increases from analysts following the successful divestment of its European subsidiary, Bressner Technology, for $22.4 million [1][2][3] Group 1: Analyst Ratings and Price Targets - Alliance Global raised its price target for One Stop Systems to $9 from $8.50 while maintaining a Buy rating after the sale of Bressner Technology [1] - Roth Capital also increased its price target for One Stop Systems to $9 from $8, affirming a Buy rating following the same divestment [3] Group 2: Business Performance and Strategic Moves - The sale of Bressner Technology exceeded expectations and was deemed a minimal contributor to shareholder value due to its low contribution margin [2] - Proceeds from the divestment are expected to be redirected towards future M&A opportunities to foster growth [2] - One Stop Systems is characterized as a leader in ruggedized AI, machine learning, and edge computing solutions, with the divestment resulting in a strong balance sheet [3][5]

Core Viewpoint - Azitra, Inc. has adjourned its Special Meeting originally scheduled for February 6, 2026, due to insufficient shareholder participation, with a new date set for March 6, 2026, to solicit additional votes on key proposals [1]. Group 1: Special Meeting Details - The Special Meeting was adjourned because only approximately 13% of the outstanding shares entitled to vote were represented, falling short of the required 33 1/3% quorum [1]. - The Reconvened Special Meeting will take place on March 6, 2026, at 11:00 a.m. Eastern Time, and will continue to be held in a virtual format [1]. - Stockholders are encouraged to vote their shares before the new deadline of March 6, 2026, at 10:59 a.m. Eastern Time [1]. Group 2: Proposals for Vote - Proposal One seeks approval for the issuance of more than 19.99% of the company's outstanding shares, which includes shares underlying warrants as per the Securities Purchase Agreement with Alumni Capital LP [1]. - Proposal Two allows for the adjournment of the Special Meeting if necessary to solicit additional proxies if there are insufficient votes [1]. Group 3: Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on innovative therapies for precision dermatology, with its lead program, ATR-12, targeting Netherton syndrome, a rare skin disease [1]. - The company also has an advanced program, ATR-04, aimed at treating EGFR inhibitor-associated rash, which affects approximately 150,000 people in the U.S. [1]. - Azitra's programs utilize a proprietary platform of engineered proteins and topical live biotherapeutic products, supported by artificial intelligence and machine learning technology [1].

Training large language models is still surprisingly difficult. My co-founder Eric and I have spent the last 3 years training the fusion and language models at Kenosoup Ben. And despite all the attention AIS has received, the tooling has barely improved.On any given day, we may spend significant time dealing with broken SDKs, sshing into busted GPU instances that you can only find out are busted after spinning them up for half an hour or discovering major bugs in open source tooling. Not to mention the work ...

Core Insights - Samuel Smith has extensive experience in dividend stock research and investment, holding positions as lead analyst and Vice President at reputable firms [1] - He is a Professional Engineer and Project Management Professional with degrees in Civil Engineering & Mathematics and a Master's in Engineering focused on applied mathematics and machine learning [1] - Samuel leads the High Yield Investor investing group, collaborating with Jussi Askola and Paul R. Drake to balance safety, growth, yield, and value in investment strategies [1] Company and Industry Summary - High Yield Investor offers various investment portfolios, including core, retirement, and international options, along with trade alerts and educational content for investors [1] - The group emphasizes community engagement through an active chat room for like-minded investors [1] - Samuel Smith holds long positions in several stocks, including GLD, SLV, OKE, ET, and CNQ, indicating a personal investment strategy aligned with the group's focus [1]

Company Overview - Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing peptide conjugate therapeutics targeting serious unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [3] - The company utilizes machine learning and artificial intelligence tools alongside high-speed synthesis techniques to design and manufacture its drug candidates [3] - Decoy has secured financing from institutional investors and non-dilutive capital sources, including the Massachusetts Life Sciences Seed Fund, Google AI startup program, and NVIDIA Inception program [3] Upcoming Presentation - Decoy Therapeutics will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026 [1] - Rick Pierce, the CEO of Decoy Therapeutics, will provide a corporate overview and discuss a new class of antiviral therapeutics capable of targeting multiple viral pathogens with a single drug [2] Financial and Strategic Partnerships - The company has received funding from the Biomedical Advanced Research and Development Authority (BARDA) through the QuickFire Challenge award, in collaboration with Johnson & Johnson Innovation – JLABS [3]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported adjusted operating income of $688 million or $4.61 per diluted share, with a year-end adjusted book value per share increasing by 11% to $37.87 [4][12] - In Q4 2025, adjusted operating income was $179 million or $1.23 per diluted share, compared to $1.09 per diluted share in the same period last year [12][14] - Adjusted return on equity for Q4 was 13.5% [7][12] Business Line Data and Key Metrics Changes - New insurance written in Q4 was $14 billion, up 2% sequentially and 8% year-over-year [13] - The primary insurance in force reached $273 billion in Q4, up $1 billion from Q3 2025 and $4 billion year-over-year [14] - Operating expenses for Q4 were $59 million, with an expense ratio of 24%, compared to $53 million and 22% in Q3 2025 [18] Market Data and Key Metrics Changes - Persistency was 80% in Q4, down 3 points sequentially and 2 points year-over-year [13] - The risk-weighted average FICO score of the insurance in-force portfolio was 746, with a risk-weighted average loan-to-value ratio of 93% [8] Company Strategy and Development Direction - The company is focused on disciplined capital allocation, supporting existing policyholders, and investing in business growth while returning excess capital to shareholders [9][10] - The company plans to return approximately $500 million to shareholders in 2026, supported by a strong capital position and effective risk management [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the uncertain macro environment and highlighted strong long-term housing demand driven by demographic trends [23] - The company remains engaged with policymakers regarding housing affordability and supply constraints, indicating a proactive approach to evolving regulatory environments [31][32] Other Important Information - The company received multiple credit ratings upgrades and industry awards, reflecting its commitment to excellence and employee experience [6][7] - The PMIER sufficiency ratio was 162%, providing significant financial flexibility [19] Q&A Session Summary Question: Capital return guidance for 2026 - Management is confident in delivering $500 million back to shareholders but will evaluate market dynamics and business performance throughout the year [25][26] Question: Regulatory environment concerns - Management is actively engaged with policymakers on various topics, including affordability and inventory challenges, and is monitoring potential regulatory changes [30][32] Question: Mortgage market expectations for 2026 - The company anticipates a 10%-15% increase in mortgage insurance market size based on external forecasts, with a focus on purchase originations [33][34] Question: Default rates and delinquency trends - Management expects new delinquencies to moderate, with current levels in line with expectations and historical patterns [36][38] Question: Performance of new book years - Recent book years are performing in line with pricing expectations, with no significant negative variations noted [42][44] Question: Areas of heightened risk - Management is monitoring housing markets with increased supply and declining prices, particularly in certain states, to manage risk effectively [46][47]

Core Insights - Decoy Therapeutics, Inc. announced participation in a Virtual Investor segment discussing its Global Access Commitment Agreement (GACA) with the Gates Foundation, focusing on developing a scalable manufacturing platform for peptide-conjugate therapeutics [1][2] Group 1: Company Overview - Decoy Therapeutics is a preclinical-stage biotechnology company utilizing machine learning and AI tools alongside high-speed synthesis techniques to design and manufacture peptide conjugate drug candidates targeting unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [5] - The company has secured financing from institutional investors and non-dilutive capital sources, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [5] Group 2: Manufacturing Platform - The company is developing a flexible, globally accessible manufacturing platform for peptide-conjugate antivirals, aimed at rapid and cost-efficient production, particularly for low- and middle-income countries [2] - The platform will be validated using Decoy's intranasal pan-coronavirus fusion inhibitor, which is funded under the Gates Foundation grant [3] Group 3: Strategic Approach - Decoy's "design-for-manufacturing" approach facilitates the transition of therapeutics from laboratory development to commercial-scale production, enabling a distributed global manufacturing network to respond to emerging viral threats [3]

4Q and Full Year 2025 Earnings Presentation February 4, 2026 © 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Forward-looking statements and additional information This presentation contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as "will," "expect," "may," "would," "could," "plan," "believe," "anticipate," "intend," "estimate," "potential," "position," "forecast," "target," "gu ...

Core Insights - Quarterhill Inc. has announced a three-year contract extension with the Illinois Tollway, valued at approximately $10.7 million, to support toll revenue management and maintenance programs [2][4]. Group 1: Contract Details - The contract extension runs from January 31, 2026, through January 30, 2029, allowing Quarterhill to continue enhancing legacy back-office and roadside transactional systems critical for daily toll collection [2][3]. - The collaboration aims to ensure seamless integration with existing systems, supporting uninterrupted toll collection and enhancing system reliability [3][4]. Group 2: Company Commitment and Strategy - Quarterhill's CEO emphasized the shared commitment to safety, reliability, and customer service, highlighting the importance of maintaining critical tolling systems for a positive driver experience [4][5]. - The extension reinforces Quarterhill's long-term service to transportation agencies, showcasing its collaborative approach to delivering secure and scalable solutions for tolling operations [5][6]. Group 3: Company Overview - Quarterhill is recognized as a global leader in the Intelligent Transportation System (ITS) industry, focusing on smart infrastructure solutions that enhance mobility and reduce congestion [6]. - The company's platforms process billions of transactions annually and utilize advanced technologies like artificial intelligence and machine learning to optimize transportation networks [6].